Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Q4 2023 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Feb 15, 2024 / 01:30PM GMT
Release Date Price: €5.48 (-24.10%)
Operator

Greetings, and welcome to Arena Pharmaceuticals full year 2023 earnings call. (Operator Instructions) As reminder, this conference is being recorded. I would now like to turn the conference over to your host, Andrea Christopher, Head of Corporate Communications and Investor Relations for Aurinia Pharmaceuticals. Thank you. You may begin.

Andrea Christopher
Aurinia Pharmaceuticals Inc. - Head of Corporate Communications & IR

Thank you, operator, and thank you to everyone for joining today's call and webcast. Joining me on the call this morning are Peter Greenleaf, Aurinia's Chief Executive Officer, and Joe Miller, our Chief Financial Officer. David will review and discuss Aurinia's 2023, fourth quarter and year end financial and operational results as well as an update on our strategic review. As communicated in the company's press release issued this morning, the Company also filed its annual financial statements on Form 10 K this morning, for more information, please refer to AirMedia's filings with the US Securities and Exchange Commission and applicable

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot